Deutsche Bank Initiates Coverage on BioMarin Pharmaceuticals (BMRN) with a Buy; Two Shots on Goal in 2011 for Additional Value
Tweet Send to a Friend
Deutsche Bank initiates coverage on BioMarin Pharmaceuticals (Nasdaq: BMRN) with a Buy rating. PT $27.
Deutsche analyst says, "Biomarin belongs ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Deutsche analyst says, "Biomarin belongs ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
